GlassScriptPhysician profile
Reejis Stephen
NPI 1881981777
$4,495.84
in general payments reported to CMS, 2019-2025
30 companies · $1,365 in 2025
The $1,365 reported for 2025 was more than what 84% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $642 · 2020: $260 · 2021: $15.36 · 2022: $712 · 2023: $566 · 2024: $935 · 2025: $1,365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,828 · Education: $38.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,828.32 |
| Education | $38.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,162.94 | 2019-2025 | Krystexxa, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $622.97 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $395.98 | 2019-2025 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $333.06 | 2019-2025 | Jynarque, Voyxact |
| Travere Therapeutics, INC. | $245.22 | 2023-2025 | Filspari |
| Akebia Therapeutics INC | $232.62 | 2019-2025 | Vafseo, Auryxia |
| Mallinckrodt Enterprises LLC | $152.97 | 2019 | |
| Novo Nordisk INC | $142.14 | 2019-2025 | Ozempic, Rybelsus |
| Vantive US Healthcare LLC | $128.34 | 2025 | |
| Calliditas Therapeutics US INC. | $128.10 | 2022-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $124.99 | 2023 | Krystexxa |
| Lilly USA, LLC | $106.00 | 2020-2024 | Jardiance |
| Mallinckrodt Hospital Products INC. | $93.61 | 2020-2022 | |
| Vifor Pharma, INC. | $74.74 | 2020-2024 | Veltassa, Korsuva |
| Daiichi Sankyo INC. | $70.11 | 2022-2024 | Injectafer |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $68.05 | 2022-2025 | Shingrix, Arexvy, Benlysta |
| Opko Pharmaceuticals, LLC | $59.87 | 2022-2024 | Rayaldee |
| Boston Scientific Corporation | $51.96 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.42 | 2025 | Jardiance |
| Fresenius USA Marketing, INC. | $42.40 | 2019-2020 | |
| Ardelyx, INC. | $35.15 | 2024-2025 | Ibsrela |
| Pfizer INC. | $28.14 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $26.47 | 2022 | |
| Scpharmaceuticals INC. | $24.04 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $20.06 | 2019 | |
| Amarin Pharma, INC. | $18.62 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $17.19 | 2019 | |
| Nxstage Medical, INC. | $16.57 | 2025 | Nxstage System One |
| Novartis Pharmaceuticals Corporation | $16.28 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reejis Stephen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.